Shopping Cart
Remove All
Your shopping cart is currently empty
Otelixizumab (Synonyms: TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3)
Catalog No. T76754 Copy Product Info
🥰Excellent
Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases.
Otelixizumab
Copy Product Info🥰Excellent
Catalog No. T76754
Synonyms TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3
Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases.
Otelixizumab
Cas No. 881191-44-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $169 | In Stock | In Stock | |
| 5 mg | $448 | In Stock | In Stock | |
| 10 mg | $715 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,460 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.13% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases. |
| In vitro | Methods: Isolated intrinsic monocyte layer (LPMC) and mucosal tissue explants were incubated with Otelixizumab for 24-48 hours. The production of inflammatory cytokines was determined by enzyme-linked immunosorbent assay. Results: Incubation of LPMC with Otelixizumab reduced the production of interferon gamma, interleukin (IL) -17A, and other inflammatory cytokines and chemokines, while increasing the production of IL-10.[1] |
| In vivo | Human CD3ε chain (nod-HUCdε) transgenic mice treated with Otelixizumab (50 μg/ day, 5 days, intravenously) experienced remission of diabetes symptoms in 47% of mice.[2] |
| Synonyms | TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD3 |
| Molecular Weight | 144.58 kDa |
| Cas No. | 881191-44-2 |
| Isotype | Human IgG1 lambda2 |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Otelixizumab | purchase Otelixizumab | Otelixizumab cost | order Otelixizumab | Otelixizumab in vivo | Otelixizumab in vitro | Otelixizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.